Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SNCA | P37840 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17371150 | 0.93 | NPC1 (0.61) | POLBKMT2AMAPTMEN1GAA | |
| SCHEMBL3272089 | 0.91 | MAPT (0.69) | POLBKMT2AMAPTMEN1GAA | |
| SCHEMBL9594129 | 0.85 | DRD4 (0.53) | POLBKMT2AMAPTMEN1GAA | |
| SCHEMBL11838896 | 0.84 | MAPT (0.84) | KMT2AMAPTMEN1GAATP53 | |
| SCHEMBL28191314 | 0.83 | MAPT (0.71) | POLBKMT2AMAPTMEN1GAA | |
| SCHEMBL855997 | 0.82 | CACNA1B (0.58) | KMT2AMAPTMEN1GAATP53 | |
| N-Benzyl-4-Methoxyaniline SCHEMBL1757104 | 0.81 | HIF1A (0.69) | KMT2AMAPTMEN1GAATP53 | |
| SCHEMBL23873637 | 0.81 | ALDH1A1 (0.72) | POLBKMT2AMAPTMEN1GAA | |
| SCHEMBL11215247 | 0.81 | CACNA1B (0.60) | KMT2AMAPTMEN1GAAL3MBTL1 | |
| SCHEMBL1924100 | 0.80 | HTT (0.78) | KMT2AMAPTMEN1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0606858-B1 | Liquid crystal compositions and liquid crystal display devices | CHISSO CORP (JP) | 2000-04-26 | — | — | EP | claimed |
| EP-4721766-A1 | COMBINATION OF (ANTI-HER3 ANTIBODY)-DRUG CONJUGATE AND RASG12C INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2026-04-08 | — | — | EP | disclosed |
| WO-2022004388-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2022-01-06 | — | — | WO | disclosed |
| WO-2021256297-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE | リードファーマ株式会社 | 2021-12-23 | — | — | WO | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2530154-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2530155-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2530153-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2386636-B1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN MRNA PRECURSOR | MATSUO MASAFUMI (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-9243026-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20030144316-A1 | Remedies | TAKARA BIO INC. (JP) | 2003-07-31 | — | — | US | disclosed |
| US-20030004208-A1 | Process for producing stereoisomer of pyrrolidine derivative | EISAI CO., LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1256573-A1 | Process for producing stereoisomer of pyrrolidine derivative | Eisai Co., Ltd. (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-1254658-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1231210-A2 | Azole antifungal agents, processes for the preparation thereof, and intermediates | Eisai Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1099440-A1 | THERAPEUTIC AGENTS | Takara Shuzo Co, Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| US-5792781-A | EFFECTIVE AGAINST DERMATOMYCOSIS/VISCEROMYCOSIS CAUSED BY FUNGI, I.E., CANDIDA ALBICANS | EISAI CO., LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5789429-A | FUNGICIDE | EISAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5648372-A | TRIAZOLES | EISAI CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004208-A1 | Process for producing stereoisomer of pyrrolidine derivative | DHPS, SQLE, FDFT1 | POLB 929/4885KMT2A 1523/4885MAPT 3664/4885 |
| US-20030144316-A1 | Remedies | NGF, BDNF, NTRK2 | POLB 4436/4885KMT2A 3404/4885MAPT 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.